Efficacy and safety of neoadjuvant therapy with TCbHP regimen for human epidermal growth factor receptor 2-positive breast cancer
10.3760/cma.j.cn115355-20230825-00068
- VernacularTitle:TCbHP方案新辅助治疗人表皮生长因子受体2阳性乳腺癌的效果和安全性
- Author:
Donghong XU
1
;
Xiangdong WU
;
Shibo ZHANG
;
Yongtao DU
;
Chongzhu HU
;
Enqing WANG
Author Information
1. 保定市第一中心医院乳腺外一科，保定 071000
- Keywords:
Breast neoplasms;
Human epidermal growth factor receptor 2;
Neoadjuvant therapy;
Treatment outcome;
Adverse effects
- From:
Cancer Research and Clinic
2024;36(8):590-593
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the efficacy and safety of neoadjuvant therapy with trastuzumab and pertuzumab combined with taxane and platinum drugs (TCbHP) regimen for human epidermal growth factor receptor 2 (HER2)-positive breast cancer.Methods:A retrospective case series study was conducted. The clinical data of HER2-positive breast cancer patients who received neoadjuvant therapy with 21-day TCbHP regimen and completed subsequent surgery in 11 tertiary-level hospitals in Hebei Province from June 2019 to December 2021 were retrospectively analyzed, and the total pathological complete remission (tpCR) rate, the incidence of grade ≥3 adverse events, and the completion rate of the established regimen were statistically analyzed.Results:A total of 78 female patients were included and the median age [ M ( Q1, Q3)] was 54.0 years (48.5 years, 57.5 years). The tpCR rate was 64.1% (50/78). Subgroup analysis showed that the tpCR rate in the HER2 immunohistochemistry (IHC)+++ group was higher than that in the HER2 IHC++ and fluorescence in situ hybridization-positive group [68.6% (48/70) vs. 25.0% (2/8)], and the difference was statistically significant ( χ2 = 4.18, P = 0.041); the tpCR rate in the hormone-receptor negative group was higher than that in the hormone-receptor positive group [81.8% (27/33) vs. 51.1% (23/45)], and the difference was statistically significant ( χ2 = 7.80, P = 0.005); the tpCR rate in the albumin-bound paclitaxel group was higher than that in the docetaxel group [72.3% (34/47) vs. 48.3% (14/29)], and the difference was statistically significant ( χ2 = 4.46, P = 0.035). The incidence of ≥ grade 3 adverse reactions was 12.8% (10/78) in 78 patients, and the completion rate of the established regimen was 92.3% (72/78). Conclusions:Neoadjuvant therapy with TCbHP regimen for HER2-positive breast cancer shows a definite efficacy, good safety and tolerance.
